NOTUM PROTEIN MODULATORS AND METHODS OF USE
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
1 - 101 . (canceled)
102 . An isolated antibody selected from:
an antibody comprising residues 24-34 of SEQ ID NO: 14 for CDR-L1, residues 50-56 of SEQ ID NO: 14 for CDR-L2, residues 89-97 of SEQ ID NO: 14 for CDR-L3, residues 31-35 of SEQ ID NO: 12 for CDR-H1, residues 50-65 of SEQ ID NO: 12 for CDR-H2 and residues 95-102 of SEQ ID NO: 12 for CDR-H3, wherein the residues are numbered according to Kabat;
an antibody comprising residues 24-34 of SEQ ID NO: 18 for CDR-L1, residues 50-56 of SEQ ID NO: 18 for CDR-L2, residues 89-97 of SEQ ID NO: 18 for CDR-L3, residues 31-35 of SEQ ID NO: 16 for CDR-H1, residues 50-65 of SEQ ID NO: 16 for CDR-H2 and residues 95-102 of SEQ ID NO: 16 for CDR-H3, wherein the residues are numbered according to Kabat;
an antibody comprising residues 24-34 of SEQ ID NO: 50 for CDR-L1, residues 50-56 of SEQ ID NO: 50 for CDR-L2, residues 89-97 of SEQ ID NO: 50 for CDR-L3, residues 31-35 of SEQ ID NO: 48 for CDR-H1, residues 50-65 of SEQ ID NO: 48 for CDR-H2 and residues 95-102 of SEQ ID NO: 48 for CDR-H3, wherein the residues are numbered according to Kabat;
an antibody comprising residues 24-34 of SEQ ID NO: 58 for CDR-L1, residues 50-56 of SEQ ID NO: 58 for CDR-L2, residues 89-97 of SEQ ID NO: 58 for CDR-L3, residues 31-35 of SEQ ID NO: 56 for CDR-H1, residues 50-65 of SEQ ID NO: 56 for CDR-H2 and residues 95-102 of SEQ ID NO: 56 for CDR-H3, wherein the residues are numbered according to Kabat; and
an antibody comprising residues 24-34 of SEQ ID NO: 98 for CDR-L1, residues 50-56 of SEQ ID NO: 98 for CDR-L2, residues 89-97 of SEQ ID NO: 98 for CDR-L3, residues 31-35 of SEQ ID NO: 96 for CDR-H1, residues 50-65 of SEQ ID NO: 96 for CDR-H2 and residues 95-102 of SEQ ID NO: 96 for CDR-H3, wherein the residues are numbered according to Kabat;
wherein the antibody binds to Notum.